

betrixaban (BEVYXXA)

Diagnosis Considered for Coverage:

- Prevention of venous thromboembolism (VTE) in adults hospitalized for an acute medical illness who are at risk for VTE

Coverage Criteria:

For diagnosis listed above:

- Bevyxxa was started in hospital setting, **and**
- Dose does not exceed 80 mg per day.

Coverage Duration: up to 42 days

Effective Date: 11/30/2022